Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Melphalan with Amifostine and Stem Cell Support in Cancer
NCT00003425Phase 2Completed
- Sponsor
- University of Kentucky
- Start
- Dec 1997
- Primary completion
- Jul 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in breast cancer, leukemia, lymphoma and 4 more, sponsored by University of Kentucky. Primary endpoint: Maximum Tolerated Dose. Started Dec 1997; status: completed.
02
Drugs
amifostine
03
Conditions
breast cancerleukemialymphomaneuroblastomaovarian cancer
Beyond the preview
Go deeper on NCT00003425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003425.